Invicta Diagnostic Ltd
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions [1]
- Market Cap ₹ 85.7 Cr.
- Current Price ₹ 68.2
- High / Low ₹ 105 / 58.1
- Stock P/E 15.5
- Book Value ₹ 39.0
- Dividend Yield 0.00 %
- ROCE 22.8 %
- ROE 17.3 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 41.2 days to 75.8 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 3.50 | 16.27 | 20.28 | |
| 2.03 | 9.88 | 12.63 | |
| Operating Profit | 1.47 | 6.39 | 7.65 |
| OPM % | 42.00% | 39.27% | 37.72% |
| 1.34 | 1.46 | 1.13 | |
| Interest | 0.01 | 0.03 | 0.04 |
| Depreciation | 0.38 | 0.95 | 1.49 |
| Profit before tax | 2.42 | 6.87 | 7.25 |
| Tax % | 0.83% | 21.54% | 23.86% |
| 2.40 | 5.38 | 5.53 | |
| EPS in Rs | 182.51 | 6.39 | 4.40 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 0.13 | 8.42 | 12.57 |
| Reserves | 9.30 | 6.39 | 36.52 |
| 0.00 | 0.00 | 0.00 | |
| 1.63 | 2.68 | 3.88 | |
| Total Liabilities | 11.06 | 17.49 | 52.97 |
| 4.59 | 3.85 | 7.42 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 4.20 | 8.00 | 16.64 |
| 2.27 | 5.64 | 28.91 | |
| Total Assets | 11.06 | 17.49 | 52.97 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 5.05 | 4.13 | 3.20 | |
| -9.51 | -4.22 | -12.60 | |
| 5.35 | 0.00 | 29.79 | |
| Net Cash Flow | 0.89 | -0.08 | 20.40 |
| Free Cash Flow | 0.08 | 3.92 | -1.90 |
| CFO/OP | 344% | 88% | 42% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 74.04 | 53.62 | 9.00 |
| Inventory Days | 378.04 | 94.53 | 79.53 |
| Days Payable | 977.68 | 73.53 | 175.36 |
| Cash Conversion Cycle | -525.60 | 74.62 | -86.84 |
| Working Capital Days | -1.04 | 48.91 | 75.77 |
| ROCE % | 56.93% | 22.81% |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Average revenue per test (ARPT) INR |
|
||
| Individual consumer business revenue share % |
|||
| Number of diagnostic centres centres |
|||
| Number of patients served patients |
|||
| Number of tests per patient visit tests per patient |
|||
| Number of tests performed tests |
|||
| Radiology revenue share % |
|||
Extracted by Screener AI
Documents
Announcements
-
Resignation of Director/KMP/SMP
29 July 2026 - Invicta Diagnostic Limited has informed about Resignation of Director/KMP/SMP
-
Outcome of Board Meeting
29 July 2026 - On 29 July 2026, Invicta appointed Sanket Jain Managing Director and accepted two resignations.
-
Trading Window
23 July 2026 - Trading window closed from 23 July 2026 until 48 hours after 29 July board meeting on management changes.
-
Change in Director(s)
23 July 2026 - Rohit Srivastava and Konica Srivastava resign; board meets July 29, 2026 to appoint MD and sell LLP stake.
-
Change in Management
20 July 2026 - Porteus Pathogenius LLP partner changed on 20 July 2026; controlling interest unchanged.
Concalls
-
May 2026Transcript PPT
Business Overview:[1]
IDL is a diagnostic services company operating across the MMR Region under the consumer brand P C Diagnostics, offering integrated radiology and pathology services with a focus on MRI, CT, and PET-CT. The company is supported by a structured hub-and-spoke network.